Literature DB >> 7261542

Increased intralymphocytic sodium content in essential hypertension: an index of impaired Na+ cellular metabolism.

E Ambrosioni, F V Costa, L Montebugnoli, F Tartagni, B Magnani.   

Abstract

1. The sodium concentration in lymphocytes was measured in a group of 66 normotensive subjects (40 without familial hypertension and 26 with familial hypertension), in a group of 81 patients with essential hypertension and in a group of 14 patients with secondary hypertension. 2. The mean value (+/- SD) in normotensive subjects with no history of familial hypertension was 21.9 +/- 3.1 mmol/kg wet weight, which was significantly lower (P less than 0.005) than that of normotensive subjects with familial hypertension (mean value 27.9 +/- 4.2 mmol/kg). Lymphocyte sodium concentration was significantly higher in patients with essential hypertension (33.2 +/- 3.3 mmol/kg; P less than 0.001) than in the subjects with normal blood pressure without familial hypertension. 3. In the patients with essential hypertension there was a significant correlation between lymphocyte sodium concentration and systolic (P less than 0.005), diastolic (P less than 0.001) and mean (P less than 0.001) blood pressure. In the normotensive subjects there was no correlation between the lymphocyte sodium concentration and the blood pressure. 4. The patients with secondary forms of hypertension had normal lymphocyte sodium concentration, except in the case of Conn's disease. 5. Incubation with ouabain increased lymphocyte sodium concentration in the normotensive subjects and patients with essential hypertension; the final sodium concentration was similar in the two groups. 6. When lymphocytes from normotensive subjects without familial hypertension were incubated in plasma of patients with essential hypertension there was an increase in their sodium content.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7261542     DOI: 10.1042/cs0610181

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  12 in total

1.  Glimpses of the mechanisms of hypertension.

Authors:  P F Semple; A F Lever
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

2.  Reversible inhibition of leucocyte sodium pumps by a circulating serum factor in essential hypertension.

Authors:  V M Oh; E A Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

Review 3.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Blood pressure in essential hypertension correlates with the concentration of a circulating inhibitor of the sodium pump.

Authors:  K Moreth; R Kuske; D Renner; W Schoner
Journal:  Klin Wochenschr       Date:  1986-03-03

5.  Red cell membrane sodium transport: possible genetic role and use in identifying patients at risk of essential hypertension.

Authors:  J E Deal; V Shah; G Goodenough; M J Dillon
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

6.  Effects of aldosterone on intralymphocytic sodium and potassium in patients with essential hypertension.

Authors:  M Wehling; S Kuhls; U Kuhnle; K Theisen
Journal:  Klin Wochenschr       Date:  1990-01-19

7.  Na+/Ca2+ exchange-mediated calcium entry in human lymphocytes.

Authors:  M Balasubramanyam; C Rohowsky-Kochan; J P Reeves; J P Gardner
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  [Cation flux in erythrocytes of patients with essential hypertension].

Authors:  K H Gless; U Roelcke; W Fiehn; J F Mann; K Schaz; U Sütterlin; G A Speck
Journal:  Klin Wochenschr       Date:  1983-05-16

Review 9.  Alterations in sodium metabolism as an etiological model for hypertension.

Authors:  P Lijnen
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

10.  Measurement of digitalis-like compound in plasma: application in studies of essential hypertension.

Authors:  M A Devynck; M G Pernollet; J B Rosenfeld; P Meyer
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.